Pressmeddelande

BioStock: Full phase II results of uPAR-PET in glioblastoma published

Cision Publicerad: 08 Nov 14:25

Curasight has published the full data from an investigator-initiated phase II trial evaluating its uTRACE imaging technology in brain cancer patients in the peer-reviewed journal EJNMMI Research. The results – which were first reported in connection with an oral presentation at a conference last year – supports the strategy to develop uTRACE and the therapeutic uTREAT in parallel.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/full-phase-ii-results-of-upar-pet-in-glioblastoma-published/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Curasight

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!